Bank Julius Baer & Co. Ltd Zurich Invests $6.04 Million in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 65,070 shares of the medical equipment provider's stock, valued at approximately $6,037,000. Bank Julius Baer & Co. Ltd Zurich owned approximately 0.09% of Lantheus at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Wilmington Savings Fund Society FSB bought a new stake in Lantheus during the third quarter worth about $25,000. Kestra Investment Management LLC purchased a new position in shares of Lantheus during the fourth quarter valued at approximately $27,000. UMB Bank n.a. boosted its position in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after purchasing an additional 134 shares in the last quarter. RiverPark Advisors LLC purchased a new stake in shares of Lantheus in the 3rd quarter worth approximately $74,000. Finally, Farther Finance Advisors LLC increased its position in Lantheus by 226.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 758 shares of the medical equipment provider's stock valued at $83,000 after buying an additional 526 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on LNTH. StockNews.com cut Lantheus from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st. JMP Securities restated a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group assumed coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 target price on the stock. Finally, Truist Financial boosted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $132.86.

Remove Ads

Insider Transactions at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company's stock.

Lantheus Trading Down 1.5 %

NASDAQ:LNTH traded down $1.56 during trading hours on Thursday, reaching $99.29. The company had a trading volume of 724,120 shares, compared to its average volume of 947,722. The firm's 50 day moving average price is $91.66 and its 200-day moving average price is $96.89. The firm has a market cap of $6.80 billion, a price-to-earnings ratio of 16.52 and a beta of 0.38. Lantheus Holdings, Inc. has a 52 week low of $56.44 and a 52 week high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.